OCT 18, 2019 11:00 AM PDT

AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia

WRITTEN BY: Nupur Srivastava

To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The product provides innovative standards for analytical BCR-ABL test methods in chronic myeloid leukemia (CML) disease. 

Chronic myeloid leukemia (CML) is a cancer of the blood-forming cells, called myeloid cells, found in the bone marrow. In CML, the bone marrow produces more white blood cells that usually are involved in fighting infection. 

BCR-ABL1 is a gene sequence that confirms the diagnosis of Chronic Myeloid Leukemia (CML), persistent bone marrow cancer. The detected gene is present in abnormal chromosome 22 of humans. In CML, part of chromosome 9 breaks off and bonds to a section of chromosome 22, forming the fusion chromosome. The abnormal BCR-ABL1 gene encodes an abnormal protein (tyrosine kinase) that is responsible for the development of CML.

Different testing types (cytogenetics, fluorescence in-situ hybridization, genetic molecular) are available to diagnose CML. The Acrometrix BCR-ABL external control panel is launched to quantitate BCR-ABL RNA accurately. The first of its kind, the product is useful to make a critical, timely, patient treatment decisions. The test product intends for research-use-only. The testing method can monitor assay performance at every clinical stage due to its expanded dynamic range.

"The Acrometrix BCR-ABL Panel is the first full-process molecular control for challenging validated BCR-ABL assay performance, providing researchers and laboratorians with greater confidence utilizing a highly characterized product," said Fernando Beils, vice president and general manager of Clinical Diagnostics for Thermo Fisher. "Additionally, this new molecular control panel is traceable to the new World Health Organization (WHO) standards for genetic reference panels for the quantitation of BCR-ABL. This provides assurance to laboratory staff that there is accuracy in the measurement of their assay results."

Sources: AmericanCancerSociety, ThermoFisherScientific

About the Author
You May Also Like
SEP 12, 2020
Cardiology
Is Hyperuricemia an Indicator of Aortic Disease?
SEP 12, 2020
Is Hyperuricemia an Indicator of Aortic Disease?
Living in a culture of excess can have its benefits, but also its drawbacks. Diabetes is a common disease that is gettin ...
SEP 07, 2020
Cell & Molecular Biology
With Nanopores, Small Samples Detect Diseases
SEP 07, 2020
With Nanopores, Small Samples Detect Diseases
If you've ever been through a battery of tests while doctors try to find a diagnosis for an ailment, you know that many ...
OCT 06, 2020
Clinical & Molecular DX
A Smart Tattoo That Could Save Your Life
OCT 06, 2020
A Smart Tattoo That Could Save Your Life
Color-changing tattoos, powered by nanotechnology, that sense imbalances in your biochemistry providing a visual signal ...
OCT 13, 2020
Clinical & Molecular DX
Test for Diabetes Checks If the Liver Is Responding
OCT 13, 2020
Test for Diabetes Checks If the Liver Is Responding
Glucagon is a hormone that prevents blood glucose levels from dropping too low by stimulating the liver to convert store ...
OCT 23, 2020
Clinical & Molecular DX
Follow Your Heart: A Genetic Predictor of Cardiovascular Disease
OCT 23, 2020
Follow Your Heart: A Genetic Predictor of Cardiovascular Disease
Cardiovascular disease is the leading cause of death globally, resulting in the loss of nearly 18 million lives each yea ...
NOV 27, 2020
Clinical & Molecular DX
From Months to Hours - Digital Tools Accelerate Dermatological Diagnoses
NOV 27, 2020
From Months to Hours - Digital Tools Accelerate Dermatological Diagnoses
Getting that nasty rash tested isn’t always a straightforward process. Dermatologists have notoriously long waitli ...
Loading Comments...